REC.MI · MIL · Healthcare
Recordati Industria Chimica e Farmaceutica S.p.A.
Also onConsensus Drift
Implied value per share
EUR 68.71
Market price
EUR 52.70
Implied upside
+30.4%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (EUR). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | EUR 2.9bn | EUR 3.3bn | EUR 3.7bn | EUR 4.2bn | EUR 4.7bn | +12.2% |
| EBIT | EUR 804.3m | EUR 902.5m | EUR 1.0bn | EUR 1.1bn | EUR 1.3bn | +12.2% |
| NOPAT | EUR 619.8m | EUR 695.5m | EUR 780.4m | EUR 875.7m | EUR 982.6m | +12.2% |
| Add depreciation & amortisation | EUR 210.5m | EUR 236.2m | EUR 265.0m | EUR 297.4m | EUR 333.7m | +12.2% |
| Less capital expenditure | EUR -464.3m | EUR -520.9m | EUR -584.5m | EUR -655.9m | EUR -736.0m | +12.2% |
| Less increase in working capital | EUR -154.4m | EUR -173.3m | EUR -194.4m | EUR -218.2m | EUR -244.8m | +12.2% |
| Free cashflow to firm | EUR 211.6m | EUR 237.4m | EUR 266.4m | EUR 299.0m | EUR 335.5m | +12.2% |
| Discount factor | 0.9638 | 0.8952 | 0.8316 | 0.7724 | 0.7175 | - |
| Present value | EUR 203.9m | EUR 212.6m | EUR 221.6m | EUR 230.9m | EUR 240.7m | +4.2% |
| Present Value Of The Forecast | EUR 1.1bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 4.20% | USD assumption - no free live source available for this market (assumption) |
| Equity risk premium | 6.50% | Market assumption |
| Beta | 0.687 | Reported 0.533, pulled toward 1.0 (Blume) |
| Cost of equity | 8.67% | Risk-free + beta x equity risk premium |
| Cost of debt | 4.20% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | EUR 10.8bn | 81.4% of capital |
| Total debt | EUR 2.5bn | 18.6% of capital, book value as a proxy |
| Tax rate | 22.9% | Effective, capped at statutory |
| WACC | 7.66% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
93% of EV
- Forecast FCFF, final year
- EUR 335.5m
- Capex at depreciation, working capital in reinvestment
- EUR 1.2bn
- Less reinvestment at g/ROIC (9.8% of NOPAT)
- EUR -116.1m
- Capitalised
- EUR 1.1bn
- ROIC (reported)
- 25.6%
- Terminal value, undiscounted
- EUR 21.3bn
- Terminal value, discounted
- EUR 15.3bn
- Enterprise value
- EUR 16.4bn
- Less net debt
- EUR 2.0bn
- Equity value
- EUR 14.4bn
Exit at 13.9x EBITDA
94% of EV
- Terminal value, undiscounted
- EUR 22.3bn
- Terminal value, discounted
- EUR 16.0bn
- Enterprise value
- EUR 17.1bn
- Less net debt
- EUR 2.0bn
- Equity value
- EUR 15.1bn
Spread between methods: 5%.
Sensitivity
Value per share (EUR) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 5.66% | 97.84 | 109.95 | 125.86 | 147.73 | 179.71 |
| 6.66% | 74.51 | 81.58 | 90.34 | 101.46 | 116.09 |
| 7.66% | 58.86 | 63.36 | 68.71 | 75.20 | 83.23 |
| 8.66% | 47.67 | 50.70 | 54.21 | 58.32 | 63.22 |
| 9.66% | 39.29 | 41.42 | 43.83 | 46.60 | 49.80 |
Outlined: this model. Green text: above today's price of 52.70. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 12.2% | 6.5% | -5.7pp |
| EBIT margin | 27.4% | 21.6% | -5.8pp |
| Discount rate | 7.7% | 8.8% | +1.1pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.